Latest Press Releases
Aug 3, 2017 • 7:00am EDT
Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results
-- SYN-004 (ribaxamase) Receives Breakthrough Therapy Designation from FDA for Prevention of CDI -- -- Three Ribaxamase Presentations to be Included at Infectious Disease Week™ (ID Week) 2017 -- -- Conference Call Today, August 3, 2017, at 8:30 a.m. EDT -- ROCKVILLE, Md., Aug. 3, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the three months ended June 30, 2017. ...